United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2017_register
executive
2017-07-08
article
Prospective Grant of Exclusive Patent License: Composition and Methods for Delivering Inhibitory Oligonucleotides for the Treatment of Pancreatic Cancer
Notices
D09002ee1bdbbe89e
D09002ee1bdbbe8ed
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
The National Institute on Aging, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to VeriLuce Therapeutics (``VLT'') located in Toronto, ON, Canada.
82 FR 31783
https://www.govinfo.gov/app/details/FR-2017-07-10/2017-14370
2017-14370
fr10jy17-44
4140-01-P
https://www.govinfo.gov/app/details/FR-2017-07-10/2017-14370
https://www.govinfo.gov/content/pkg/FR-2017-07-10/html/2017-14370.htm
https://www.govinfo.gov/content/pkg/FR-2017-07-10/pdf/2017-14370.pdf
2 p.
31783
31784
82 FR 31783
Prospective Grant of Exclusive Patent License: Composition and Methods for Delivering Inhibitory Oligonucleotides for the Treatment of Pancreatic Cancer; Federal Register Vol. 82, Issue
NOTICE
2017-14370
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2017-07-25
4140-01-P
2017-14370
Notice.
The National Institute on Aging, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to VeriLuce Therapeutics (``VLT'') located in Toronto, ON, Canada.
Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 25, 2017 will be considered.
Exclusive Patent Licenses:
Composition and Methods for Delivering Inhibitory Oligonucleotides for Treatment of Pancreatic Cancer
,
vathyams@mail.nih.gov
Federal Register
Vol. 82, no. 130
Office of the Federal Register, National Archives and Records Administration
2017-07-10
continuing
daily
deposited
born digital
181 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2017-07-10
P0b002ee19578d227
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr10jy17
https://www.govinfo.gov/app/details/FR-2017-07-10
https://www.govinfo.gov/content/pkg/FR-2017-07-10/pdf/FR-2017-07-10.pdf
https://www.govinfo.gov/content/pkg/FR-2017-07-10/xml/FR-2017-07-10.xml
fdlp
31715
31886
DGPO
2017-07-08
2023-04-28
FR-2017-07-10
machine generated
eng
FR
FR-2017-07-10
82
130